PMC:7394275 / 20077-20735 JSONTXT

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T296","span":{"begin":147,"end":153},"obj":"UBERON:0007023"},{"id":"T297","span":{"begin":381,"end":395},"obj":"CHEBI:2682;CHEBI:2682"},{"id":"T298","span":{"begin":415,"end":426},"obj":"CHEBI:5100;CHEBI:5100"},{"id":"T299","span":{"begin":440,"end":451},"obj":"CHEBI:46081;CHEBI:46081"},{"id":"T300","span":{"begin":477,"end":488},"obj":"CHEBI:46081;CHEBI:46081"},{"id":"T301","span":{"begin":491,"end":502},"obj":"CHEBI:5100;CHEBI:5100"},{"id":"T302","span":{"begin":506,"end":520},"obj":"CHEBI:2682;CHEBI:2682"},{"id":"T303","span":{"begin":521,"end":533},"obj":"CHEBI:23614;CHEBI:23614"},{"id":"T304","span":{"begin":536,"end":547},"obj":"CHEBI:46081;CHEBI:46081"},{"id":"T305","span":{"begin":578,"end":589},"obj":"CHEBI:46081;CHEBI:46081"},{"id":"T306","span":{"begin":646,"end":657},"obj":"CHEBI:46081;CHEBI:46081"},{"id":"T89127","span":{"begin":147,"end":153},"obj":"UBERON:0007023"},{"id":"T93441","span":{"begin":381,"end":395},"obj":"CHEBI:2682;CHEBI:2682"},{"id":"T94698","span":{"begin":415,"end":426},"obj":"CHEBI:5100;CHEBI:5100"},{"id":"T49658","span":{"begin":440,"end":451},"obj":"CHEBI:46081;CHEBI:46081"},{"id":"T9605","span":{"begin":477,"end":488},"obj":"CHEBI:46081;CHEBI:46081"},{"id":"T18149","span":{"begin":491,"end":502},"obj":"CHEBI:5100;CHEBI:5100"},{"id":"T36092","span":{"begin":506,"end":520},"obj":"CHEBI:2682;CHEBI:2682"},{"id":"T79474","span":{"begin":521,"end":533},"obj":"CHEBI:23614;CHEBI:23614"},{"id":"T28968","span":{"begin":536,"end":547},"obj":"CHEBI:46081;CHEBI:46081"},{"id":"T44295","span":{"begin":578,"end":589},"obj":"CHEBI:46081;CHEBI:46081"},{"id":"T89336","span":{"begin":646,"end":657},"obj":"CHEBI:46081;CHEBI:46081"}],"text":"The treatment recommendations can be supported by guidelines for the diagnosis, prevention, and management of cryptococcal disease in HIV-infected adults, adolescents, and children in 2018 by World Health Organization (from: https://www.who.int/hiv/pub/guidelines/cryptococcal-disease/en/). Generally, the following is recommended as the preferred regimen: (i) Induction phase for amphotericin B deoxycholate and + flucytosine, followed by fluconazole; alternative options for fluconazole + flucytosine or amphotericin B deoxycholate + fluconazole. (ii) Consolidation phase for fluconazole. (iii) Maintenance (or secondary prophylaxis) phase for fluconazole."}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T66","span":{"begin":134,"end":137},"obj":"Body_part"},{"id":"T67","span":{"begin":245,"end":248},"obj":"Body_part"}],"attributes":[{"id":"A66","pred":"fma_id","subj":"T66","obj":"http://purl.org/sig/ont/fma/fma278683"},{"id":"A67","pred":"fma_id","subj":"T67","obj":"http://purl.org/sig/ont/fma/fma278683"}],"text":"The treatment recommendations can be supported by guidelines for the diagnosis, prevention, and management of cryptococcal disease in HIV-infected adults, adolescents, and children in 2018 by World Health Organization (from: https://www.who.int/hiv/pub/guidelines/cryptococcal-disease/en/). Generally, the following is recommended as the preferred regimen: (i) Induction phase for amphotericin B deoxycholate and + flucytosine, followed by fluconazole; alternative options for fluconazole + flucytosine or amphotericin B deoxycholate + fluconazole. (ii) Consolidation phase for fluconazole. (iii) Maintenance (or secondary prophylaxis) phase for fluconazole."}

{"project":"LitCovid-PubTator","denotations":[{"id":"595","span":{"begin":172,"end":180},"obj":"Species"},{"id":"596","span":{"begin":245,"end":248},"obj":"Species"},{"id":"597","span":{"begin":381,"end":408},"obj":"Chemical"},{"id":"598","span":{"begin":415,"end":426},"obj":"Chemical"},{"id":"599","span":{"begin":440,"end":451},"obj":"Chemical"},{"id":"600","span":{"begin":477,"end":488},"obj":"Chemical"},{"id":"601","span":{"begin":491,"end":502},"obj":"Chemical"},{"id":"602","span":{"begin":506,"end":520},"obj":"Chemical"},{"id":"603","span":{"begin":521,"end":533},"obj":"Chemical"},{"id":"604","span":{"begin":536,"end":547},"obj":"Chemical"},{"id":"605","span":{"begin":578,"end":589},"obj":"Chemical"},{"id":"606","span":{"begin":646,"end":657},"obj":"Chemical"},{"id":"607","span":{"begin":110,"end":130},"obj":"Disease"},{"id":"608","span":{"begin":134,"end":146},"obj":"Disease"},{"id":"609","span":{"begin":264,"end":284},"obj":"Disease"}],"attributes":[{"id":"A595","pred":"tao:has_database_id","subj":"595","obj":"Tax:9606"},{"id":"A596","pred":"tao:has_database_id","subj":"596","obj":"Tax:12721"},{"id":"A597","pred":"tao:has_database_id","subj":"597","obj":"MESH:C059765"},{"id":"A598","pred":"tao:has_database_id","subj":"598","obj":"MESH:D005437"},{"id":"A599","pred":"tao:has_database_id","subj":"599","obj":"MESH:D015725"},{"id":"A600","pred":"tao:has_database_id","subj":"600","obj":"MESH:D015725"},{"id":"A601","pred":"tao:has_database_id","subj":"601","obj":"MESH:D005437"},{"id":"A602","pred":"tao:has_database_id","subj":"602","obj":"MESH:D000666"},{"id":"A603","pred":"tao:has_database_id","subj":"603","obj":"MESH:D003840"},{"id":"A604","pred":"tao:has_database_id","subj":"604","obj":"MESH:D015725"},{"id":"A605","pred":"tao:has_database_id","subj":"605","obj":"MESH:D015725"},{"id":"A606","pred":"tao:has_database_id","subj":"606","obj":"MESH:D015725"},{"id":"A607","pred":"tao:has_database_id","subj":"607","obj":"MESH:D016919"},{"id":"A608","pred":"tao:has_database_id","subj":"608","obj":"MESH:D015658"},{"id":"A609","pred":"tao:has_database_id","subj":"609","obj":"MESH:D016919"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"The treatment recommendations can be supported by guidelines for the diagnosis, prevention, and management of cryptococcal disease in HIV-infected adults, adolescents, and children in 2018 by World Health Organization (from: https://www.who.int/hiv/pub/guidelines/cryptococcal-disease/en/). Generally, the following is recommended as the preferred regimen: (i) Induction phase for amphotericin B deoxycholate and + flucytosine, followed by fluconazole; alternative options for fluconazole + flucytosine or amphotericin B deoxycholate + fluconazole. (ii) Consolidation phase for fluconazole. (iii) Maintenance (or secondary prophylaxis) phase for fluconazole."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T123","span":{"begin":184,"end":188},"obj":"http://purl.obolibrary.org/obo/CLO_0001185"},{"id":"T124","span":{"begin":205,"end":217},"obj":"http://purl.obolibrary.org/obo/OBI_0000245"},{"id":"T125","span":{"begin":285,"end":287},"obj":"http://purl.obolibrary.org/obo/CLO_0037161"},{"id":"T126","span":{"begin":394,"end":395},"obj":"http://purl.obolibrary.org/obo/CLO_0001021"},{"id":"T127","span":{"begin":519,"end":520},"obj":"http://purl.obolibrary.org/obo/CLO_0001021"}],"text":"The treatment recommendations can be supported by guidelines for the diagnosis, prevention, and management of cryptococcal disease in HIV-infected adults, adolescents, and children in 2018 by World Health Organization (from: https://www.who.int/hiv/pub/guidelines/cryptococcal-disease/en/). Generally, the following is recommended as the preferred regimen: (i) Induction phase for amphotericin B deoxycholate and + flucytosine, followed by fluconazole; alternative options for fluconazole + flucytosine or amphotericin B deoxycholate + fluconazole. (ii) Consolidation phase for fluconazole. (iii) Maintenance (or secondary prophylaxis) phase for fluconazole."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T115","span":{"begin":285,"end":287},"obj":"Chemical"},{"id":"T116","span":{"begin":381,"end":395},"obj":"Chemical"},{"id":"T117","span":{"begin":396,"end":408},"obj":"Chemical"},{"id":"T118","span":{"begin":415,"end":426},"obj":"Chemical"},{"id":"T119","span":{"begin":440,"end":451},"obj":"Chemical"},{"id":"T120","span":{"begin":477,"end":488},"obj":"Chemical"},{"id":"T121","span":{"begin":491,"end":502},"obj":"Chemical"},{"id":"T122","span":{"begin":506,"end":520},"obj":"Chemical"},{"id":"T123","span":{"begin":521,"end":533},"obj":"Chemical"},{"id":"T124","span":{"begin":536,"end":547},"obj":"Chemical"},{"id":"T125","span":{"begin":578,"end":589},"obj":"Chemical"},{"id":"T126","span":{"begin":592,"end":595},"obj":"Chemical"},{"id":"T127","span":{"begin":646,"end":657},"obj":"Chemical"}],"attributes":[{"id":"A115","pred":"chebi_id","subj":"T115","obj":"http://purl.obolibrary.org/obo/CHEBI_30347"},{"id":"A116","pred":"chebi_id","subj":"T116","obj":"http://purl.obolibrary.org/obo/CHEBI_2682"},{"id":"A117","pred":"chebi_id","subj":"T117","obj":"http://purl.obolibrary.org/obo/CHEBI_23614"},{"id":"A118","pred":"chebi_id","subj":"T118","obj":"http://purl.obolibrary.org/obo/CHEBI_5100"},{"id":"A119","pred":"chebi_id","subj":"T119","obj":"http://purl.obolibrary.org/obo/CHEBI_46081"},{"id":"A120","pred":"chebi_id","subj":"T120","obj":"http://purl.obolibrary.org/obo/CHEBI_46081"},{"id":"A121","pred":"chebi_id","subj":"T121","obj":"http://purl.obolibrary.org/obo/CHEBI_5100"},{"id":"A122","pred":"chebi_id","subj":"T122","obj":"http://purl.obolibrary.org/obo/CHEBI_2682"},{"id":"A123","pred":"chebi_id","subj":"T123","obj":"http://purl.obolibrary.org/obo/CHEBI_23614"},{"id":"A124","pred":"chebi_id","subj":"T124","obj":"http://purl.obolibrary.org/obo/CHEBI_46081"},{"id":"A125","pred":"chebi_id","subj":"T125","obj":"http://purl.obolibrary.org/obo/CHEBI_46081"},{"id":"A126","pred":"chebi_id","subj":"T126","obj":"http://purl.obolibrary.org/obo/CHEBI_74062"},{"id":"A127","pred":"chebi_id","subj":"T127","obj":"http://purl.obolibrary.org/obo/CHEBI_46081"}],"text":"The treatment recommendations can be supported by guidelines for the diagnosis, prevention, and management of cryptococcal disease in HIV-infected adults, adolescents, and children in 2018 by World Health Organization (from: https://www.who.int/hiv/pub/guidelines/cryptococcal-disease/en/). Generally, the following is recommended as the preferred regimen: (i) Induction phase for amphotericin B deoxycholate and + flucytosine, followed by fluconazole; alternative options for fluconazole + flucytosine or amphotericin B deoxycholate + fluconazole. (ii) Consolidation phase for fluconazole. (iii) Maintenance (or secondary prophylaxis) phase for fluconazole."}

{"project":"LitCovid-sentences","denotations":[{"id":"T102","span":{"begin":0,"end":290},"obj":"Sentence"},{"id":"T103","span":{"begin":291,"end":658},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"The treatment recommendations can be supported by guidelines for the diagnosis, prevention, and management of cryptococcal disease in HIV-infected adults, adolescents, and children in 2018 by World Health Organization (from: https://www.who.int/hiv/pub/guidelines/cryptococcal-disease/en/). Generally, the following is recommended as the preferred regimen: (i) Induction phase for amphotericin B deoxycholate and + flucytosine, followed by fluconazole; alternative options for fluconazole + flucytosine or amphotericin B deoxycholate + fluconazole. (ii) Consolidation phase for fluconazole. (iii) Maintenance (or secondary prophylaxis) phase for fluconazole."}